linafinib-resistant FLT3 mutants don't bind linifanib

Stable Identifier
R-HSA-9702997
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
linafinib-resistant FLT3 mutants don't bind linifanib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The following FLT3 mutants are resistant to linifanib-mediated inhibition:

FLT3 D835A (Nguyen et al, 2017)
FLT3 D835Y (Nguyen et al, 2017)
Literature References
PubMed ID Title Journal Year
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H

Oncotarget 2017
21471285 The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway

Hernandez-Davies, JE, Sakamoto, KM, Heinrich, MC, Tan, X, Glaser, KB, Landaw, EM, Presnell, A, Zape, JP, Griffith, D

Mol. Cancer Ther. 2011
Participants
Input
Participates
as an event of
Normal reaction
FLT3 binds type I TKI (Homo sapiens)
Functional status

Loss of function of linifanib-resistant FLT3 mutants [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-03)
Cite Us!